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Summary: The concentrations of platelet-derived growth factor in serum in 7 healthy controls (61 ± 9 years;
mean ± SD) and 10 patients (62 ± 8 years) with chronic liver disease (chronic hepatitis and/or liver cirrhosis)
were compared.
The plasma concentration of platelet-derived growth factor was below the detection limit (< 0.45 μg/l) in all the
subjects studied. The peripheral blood platelet count in patients with chronic liver disease was significantly lower
than that in control subjects. However, the concentration of platelet-derived growth factor in serum, which was
assumed to be released from platelet, was similar in patients with chronic liver disease and control subjects. These
results indicate that the mean amount of platelet-derived growth factor releasedrfrom the same number (lO9) of
platelets, calculated from the serum platelet-derived growth factor concentration and the peripheral blood platelet
count, in patients with chronic liver disease (33 ± 11 ng/109 platelets) was significantly (p < 0.01) higher than that
in control subjects (14 ± 5 ng/109 platelets).
Moreover, the amount of platelet-derived growth factor released from l O9 platelets inversely correlated with the
serum concentration of pseudocholinesterase activity (r = —0.65, p < 0.01), and correlated positively (r = 0.91,
p < 0.01) with the percent retention of indocyanine green in serum, in all subjects studied.
These findings suggest that the amount of platelet-derived growth factor releasable from platelets of patients with
chronic liver disease i$ higher than that in normal subjects and that it correlates with the severity of the disease.
Platelet-derived growth factor released from platelets may be involved in the pathophysiology of chronic liver
diseases s a local factor.
Introduction rangement of lobular architecture and fibrosis (10).
™
 Λ x , . « ., r . ,. . Liver fat-storing cells, referred to s vitamin A-contain-Platelet-denved growth factor is a glyc protem con- & „
sistiBg of two polypeptides, A^ and B-chains (1). Human ^ ΗΡ°^68 or Ito cells' which « cells of mesenchy
platelet-derived growth factor is released from the a- mal oriSin situated in the sPace of Disse> P™liferate and
granules of platelets (2-4) when platelets aggregate, Produce several matrix components in inflamed liver tis-
and is kuown to promote the proliferation of fibroblasts sue> ™d ** thou8ht to Play a central role in hver fib'
(5, 6), smooth muscle cells (7) and glial cells (8) in «>genesis (11-13). Recent studies have shown that
vitro. Therefore, human platelet-derived growth factor is platelet-derived growth factor and thrombocyte lysate
thought to participate in wound healing and the develop- promote proliferation of cultured fat-storing cells and
ment of arteriosclerosis in vivo (9). On the other hand, stimulate synthesis of extracellular matrix, suggesting
chronic liver diseases, including chronic hepatitis and the participation of platelet-derived growth factor in fi-
liver cirrhosis, are characterized by destruction and de- brosis of the liver (14-17). Thrombocytopenia, which
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is frequently seen in chronic liver diseases, has been
attributed to hypersplenism (10). Stein & Harker re-
ported that the life-span of platelets in the peripheral
circulation and Ihe nuniber of platelets in chronic liver
diseases are decreased, and that the platelets are con-
sumed in the liver (18). We previously reported that the
amount of platelet-derived growth factor in the serum of
patients with idiopathic thrombocytopenic purpura was
lovver than that in control subjects, and that it correlated
positively with the peripheral blood platelet count. Plate-
let-derived growth factor released from l O9 platelets in
patients with idiopathic thrombocytopenic purpura was
not different from that in control subjects (19). In this
study, we measured the platelet-derived growth factor
released from platelets in patients with chronic liver dis-
eases, and found that it was increased and correlated
with the severity of disease.
Materials and Methods
Subjects and sample preparation
The subjects studied consisted of 7 healthy volunteers (4 males and
3 females: 61 ± 9 years; mean ± SD) and 10 patients with chronic
liver disease (chronic hepatitis and/or liver cirrhosis; 7 males and
3 females; 62 ± 8 years). Chronic liver disease was diagnosed on
the basis of laboratory biochemical tests including serum levels
of aspartate aminotransferase, alanine amlnotransferase, lbumin,
globulin, total bilirubin and pseudocholinesterase, prothrombin
time, indocyanine green clearance, Serologie tests for hepatitis
viruses (hepatitis B virus antigen and hepatitis C virus antibody),
and by imaging including ultrasonography, computed tomography,
magnetic resonance imaging, radioisotope scanning, and angiogra-
phy. Indocyanine green clearance was determined by calculation
of the indocyanine green retention in the serum 15 min after intra-
venous injection of indocyanine green at a dose of 0.5 mg/kg body
weight. Hepatitis C virus antibody was examined by enzyme-
linked immunosorbent assay (20). None of the subjects had been
administered any drugs that would affect platelet fiinction. Blood
samples were obtained from these subjects in the rnoming after an
ovemight fast. Serum samples were prepared by allowing 5 ml of
blood to clot in a glass tube at room teji^perature for 2 h followed
by Separation of serum by centrifug tion at 1000g for 10 min.
Platelet-poor plasma was obtained from blood collected in a plastic
syringe containing 4 mmol/1 EDTA and centrifuged at 12000g for
10 min at 4 °C. All these samples were stored at -20 °C for later
analysis. The content of platelet-derived growth faetor did not in-
crease on Standing for more than 2 h or by adding 2 μιηοΐ/ΐ adenos-
ine diphosphate.
Platelet-derived growth factor determination
The platelet-derived growth factor concentration was measured
using double^step competitive radioimmunoassay (RIA) kit
(Amersham Co., Bucks, UK). In the RIA the following were used:
platelet-derived growth factor B-chain homodimer (c-sis recombi-
nant) labelled with 125I s a tracer, platelet-derived growth factor
B-chain homodimer (c-sis recombinant) s a Standard, a goat antl·
human platelet-derived growth factor polyclonal antibody for the
first antibody, and donkey anti-sheep antiserum in phosphate-buff-
ered saline with gelatin and 10% polyethylene glycol for the se-
cond antibody. The r nge of this assay is 0.45-60 μg/l.
Statistical analysis
Statistical analysis was perfonned using the Wilcoxon rank sum
test and correlations were calculated by Spearman's rank test.
Results
Table l shows the clinical and laboratory data of the
patients with chronic liver disease. On the basis of the
Tab. l Clinical and laboratory data of patients with chronic liver diseases.
Case
1
2
3
4
5
6
7
8
9
10
Mean
±SD
Age
74
53
63
59
75
54
70
60
57
57
62
±8
Sex
c?
<J
?
c??
δ
. ?ii
3
Normal
r nge
Aspar-
tate
amino-
trans-
ferase
U/l)
112
122
39
90
40
41
40
33
39
24
58
±38
0
-30
Alanine
amino-
trans-
ferase
(U/l)
44
107
55
140
63
87
35
40
41
27
64
±36
0
-32
Total
protein
(g/0
70
70
62
78
76
76
62
73
72
66
71
±5
64
-81
Albumin
(g/i)
35
39
30
40
40
47
32
42
39
31
38
±5
36
-47
Total
bili-
rubin
(mg/1)
18
10
6
9
9
9
10
7
8
6
9
±3
3
-14
Pseudo-
cholin-
esterase
(U/l)
891
2404
1175
1974
2313
4381
2012
2279
2843
1509
2178
±975
2700
-5600
Pro-
thrombin
time
(percent
of control)
(%)
n.d.
79
79
68
81
77
76
88
63
60
75
±9
80
-120
Indo-
cyanine
green
clearance
(%)
35
24
28
24
19
12
15
15
16
18
21
±7
0
-10
Haema-
tocrit
0.343
0.378
0.363
0.448
0.402
0.439
0.380
0.352
0.402
0.316
0.382
±0.042
0.38
-0.48
Platelet
count
(109/l)
30
39
40
70
87 '
120
130
150
150
160
98
±51
130
-320
Indocyanine green clearance: percent retention of indocyanine green in serum 15 minutes after injection of 0.5 mg/kg body weight, n.d.:
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results of laboratory biochemical tests and diagnostic
imaging, cases 1—5 and 7-10 were diagnosed s having
liver cirrhosis and case 6 was diagnosed s having
chronic hepatitis. In all the patients, chronic liver disease
was due to viral hepatitis; hepatitis B in case 6 and hepa-
titis C in the other cases. The mean platelet count in the
peripheral blood of patients with chronic liver disease,
which was 98 ± 51 X 109/1 (mean ± SD), was signifi-
cantly (p < 0.01) lower than that of the control subjects,
which was 211 ± 42 X 109/1.
In patients with chronic liver disease, the mean serum
platelet-derived growth factor concentration was 4.6
±1.8 μg/l (r nge 2.5-9.0 μg/l); it did not differ sig-
nificantly from that in the control subjects, which was
5.0 ± 1.7 μg/l (r nge 1.9-7.5 μg/l) (fig. la). The serum
platelet-derived growth factor concentration mainly re-
flects the amount of platelet-derived growth factor re-
leased from platelets, because the plasma platelet-de-
rived growth factor concentrations of all the subjects
studied were below the detection limit (< 0.45 μg/l).
The amount of platelet-derived growth factor released
from platelets was calculated s follows: the serum
platelet-derived growth factor concentration was cor-
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Fig. l ComparisojQ of platelet-derived growth factor concen-
trations in patients with chronic liver disease and in control sub-
jects.
a) Serum. Open circles represent individu l values and the mean
(large circle) of normal controls, and closed circles represent indi-
vidu l values and the mean (large circle) of patients with chronic
liver disease. Vertical bars denote SD. NS *= not significant.
b) Released from l O9 platelets, Serum platelet-derived growth fac-
tor concentrations were corrected for the haematocrit and expressed
s ng platelet-derived growth factor per l O9 platelets. Key s in
figure l a.
rected for the haematocrit, divided by the peripheral
blood platelet count, and expressed s ng platelet-de-
rived'growth factor per l O9 platelets. The mean amount
of platelet-derived growth factor released from the plate-
lets in patients with chronic liver disease, which was
33 ± 11 ng/109 cells, was significantly (p < 0.01)
higher than that in the control subjects, which was
14 ± 5 ng/109 cells (fig. Ib).
The amount of platelet-derived growth factor released
from l O9 platelets correlated inversely with the periph-
eral blood platelet count (r = -0.87, p < 0.01) and
serum concentration of pseudocholinesterase activity
(r = -0.65, p < 0.01), and correlated positively
(r = 0.91, p < 0.01) with the percent retention of
indocyanine green, in all the subjects studied. There was
a negative correlation (r = -0.87, p < 0.01) between
the peripheral blood platelet count and the percent reten-
tion of indocyanine green in the patients with chronic
liver disease.
Discussion
We previously reported that the mean serum platelet-
derived growth factor concentration was significantly
decreased in patients with idiopathic thrombocytopenic
purpura, and that there was a significant positive corre-
lation between blood platelet count and serum platelet-
derived growth factor concentration in the combined
group of control subjects and patients with idiopathic
thrombocytopenic purpura (19). Platelet-derived growth
factor is a local factor, and the clearance rate of platelet-
derived growth factor in the circulation in vivo is very
rapid (21). The concentrations of platelet-derived
growth factor in plasma of all normal subjects and in
patients with idiopathic thrombocytopenic purpura or
chronic liver disease were below the detection limit. The
concentrations of platelet-derived growth factor in
serum were higher than those in ADP-stimulated plasma
(22). These obseryations suggest that the serum platelet-
derived growth factor level reflects mainly the amount
of platelet-derived growth factor releasable from plate-
lets, and that the platelet-derived growth factor released
from the platelets is apparently dependent on the platelet
count in the peripheral blood in patients with idiopathic
thrombocytopenic purpura and normal subjects» The
amount of platelet-derived growth factor releasable from
the sarne number of platelets was not significantly dif-
ferent between patients with idiopathic thrombocyto-
penic purpura and normal subjects.
In the present study, although the mean platelet count in
peripheral blood was significantly lower in patients with
chronic liver disease than that in the control subjects,
the mean serum platelet-derived growth factor level in
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patients wilh chronic liver disease was not lower than
that in control subjects (fig. l a). Jorgensen et al. re-
portcd that the mean volume of platelets in patients with
chronic liver disease was smaller than that in normal
subjects (23). These findings suggest that the amount
of platelet-derived growth factor releasable from each
platelet is increased and concentrated in patients with
chronic liver disease. The mean amount of platelet-de-
rived growth factor released from platelets in patients
with chronic liver disease was significantly greater than
that in control subjects (fig. Ib). The value significantly
correlated with indicators of liver function, such äs the
serum concentration of pseudocholinesterase and the in-
docyanine green value in the combined group. Serum
pseudocholinesterase activity and indocyanine green
clearance rate are known to reflect liver function and are
thought to be markers of the progression of liver cir-
rhosis (10). In this study, we focussed on serum platelet-
derived growth factor for evaluation of the amount of
platelet-derived growth factor released from platelets,
instead of meäsuring the cellular content of platelet-de-
rived growth factor from platelet lysate. Actually, the
ratio of platelet-derived growth factor released from the
aggregated platelets to cellular platelet-derived growth
factor was 0.80 ± 0.20 (mean ± SD) in 4 healthy volun-
teers (data not shown). This observation suggests that
the majority of cellular platelet-derived growth factor is
released at the time of aggregation, and that measure-
ment of serum platelet-derived growth factor reflects the
cellular content of platelet-derived growth factor (cf.
tab. 2). Moreover, serum platelet-derived growth factor
values would reflect the amount of platelet-derived
growth factor released from platelets during platelet ag-
gregation at sites of inflammation in the liver in vivo.
Although platelet-derived growth factor is known to
bind to a2-macroglobulin (24) and other plasma pro-
teins, the effect of these binding proteins on our assay
System should be minimal, since the plasma levels of
platelet-derived growth factor studied were all below the
detection limit in our assay System.
Thrombocytopenia is often seen in patients with chronic
liver disease associated with portal hypertension and/or
hypersplenism. The life-span of platelets is shortened
and platelets are assumed to be consumed in the liver in
chronic liver diseases (18). Several types of in vivo stud-
ies have demonstrated that fat-storing cells play a central
role in liver fibrogenesis (11 — 13). Recent studies have
also shown that platelet-derived growth factor stimülates
proliferation of cultured fafcstoring cells and synthesis
of mätrix components by fat-storirig cells (14—17).
However, the source of platelet-derived growth factor in
liver fibrogenesis is unceftain. In patients with idiopathic
pulmonary fibrosis, alveolar macrophages release a large
amount of platelet-derived growth factor (25). In chronic
liver diseases, it is possible that activated macrophages,
including Kupffer cells, and/or platelets, which accumu-
late in hepatic inflammation (18, 26), release platelet^
derived growth factor. These findings suggest that the
large amount of platelet-derived growth factor released
by platelet activation in patients with chronic liver dis-
ease may be involved in the pathophysiology of chronic
liver diseases äs a locäl factor.
Further studies are requifed on the mechaiiism of in-
crease of platelet-derived growth factor in platelets in
patients with chronic liver disease, on whether platelet-
derived growth factor is released at inflammatory sites
in the liver in chronic liver disease, and on whether or
not platelet-derived growth factor aggravates the pro-
gression of chronic liver diseases in vivo.
Tab
-
2
 Platelet-derived growth factor concentrations in serum and platelet lysate in 4 healthy volunteers
Case Haema-
tocrit
Platelet count
(109/1)
Platelet-derived
growth factor
(HgÄ)
Platelet-derived
growth factor/
platelets
(ng/109 platelets)
caleulated from
1
3 ·-
4
Mean
±SD
0.48
0.41
0.40
0.39
0.42
±0.04
Whole
blood
149
162
111
341
191
±102
Platelet
lysate
93
151
102
254
150
±74
Serum
3.7
4.7
4.4
7.2
5.0
±1.5
Platelet
lysate
1.9
4.1
2.7
3.2
3.0
±0.9
Serum
12.9
17.4
23.9
12.8
16.8
±5.2
Platelet
lysate
20.6
26.8
26.5
12.5
21.6
±6.7
Ratio of platelet-
derived growth
factor/platelets
caleulated frorn
serum to that
caleulated from
platelet lysate
0.63
.0.65
0.90
1.03
0.80
±0.20
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